Quantcast

Latest Neuroendocrine tumor Stories

2009-07-07 05:30:00

THE WOODLANDS, Texas, July 7 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX1032, the company's oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. LX1032 is designed to reduce serotonin production in patients with metastatic carcinoid tumors....

2009-06-02 07:00:00

NEW YORK, June 2 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that the United States Food and Drug Administration ("FDA") granted Delcath's application for orphan-drug designation for the drug melphalan for the treatment of patients with neuroendocrine tumors. (Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO) Delcath is...

2009-04-17 07:00:00

SAN DIEGO, April 17 /PRNewswire/ -- Cylene Pharmaceuticals announced today that it will be presenting new data on recent advances of its small molecule anticancer agents during a symposium and several poster presentations at the American Association for Cancer Research (AACR) annual meeting, to be held on April 18-22 in Denver, Colorado. Cylene scientists will unveil the first public description of CX-4945, a first-in-class oral inhibitor of protein kinase CK2. CK2 overexpression is well...

965200e406012e5cd3869744713bf56e1
2009-03-13 07:15:00

Pfizer Inc. announced on Thursday that it had halted a successful trial of its cancer drug Sutent after results showed the drug slowed the progression of a rare form of pancreatic cancer.Compared to standard treatment and a placebo, Sutent substantially improved progression-free survival, the trial showed.  The company halted the trial after an independent safety board monitoring the late-stage study issued a positive recommendation.Because the trial was stopped early, patients will have...

2009-03-05 08:25:00

THE WOODLANDS, Texas, March 5 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that Dr. Philip Brown, senior vice president of clinical development at Lexicon, delivered an oral presentation at the annual meeting of the European Neuroendocrine Tumor Society (ENETS). The presentation summarized Phase 1 clinical trial results for LX1032, Lexicon's...

2009-03-02 07:10:00

New president/CEO announces timely goals for established foundation WHITE PLAINS, N.Y., March 2 /PRNewswire/ -- Several high-profile cancers are infamous for being silent killers - but they are not the only cancers that catch victims by surprise. Carcinoid cancer can go undetected for many years. Over 90% of all carcinoid/neuroendocrine tumor (NET) patients are initially incorrectly diagnosed and treated for the wrong disease. Carcinoid cancers are frequently diagnosed accidentally....

2009-02-19 07:24:00

NEW YORK, Feb. 19 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary Percutaneous Hepatic Perfusion ("PHP(TM)") System for the treatment of cancers of the liver, announced today that Dr. James F. Pingpank will present at The Fourth International Symposium on Regional Cancer Therapies, to be held February 21-23, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ) Dr. Pingpank, Adjunct Principal...

2009-01-22 11:05:00

Patients with pancreatic cancer can now see all their physicians and receive the results of tests on the same day in the same place with the recent opening of the multidisciplinary clinic at the Elkins Pancreas Center in the Dan L. Duncan Cancer Center at Baylor College of Medicine in Houston. "Pancreatic cancer is a very complex disease. There are a lot of medical issues and decisions that come with the diagnosis," said Dr. William E. Fisher, director of the Elkins Pancreas Center and...

2009-01-13 17:47:00

- Data show significant 66% reduction in risk of disease progression versus placebo - Sandostatin LAR more than doubled time without tumor growth for a median of 14 months compared to six months on placebo - Results support Sandostatin LAR as first treatment after surgery in certain patients with newly diagnosed neuroendocrine tumors (NETs) EAST HANOVER, N.J., Jan. 13 /PRNewswire/ -- Sandostatin LAR(R) Depot (octreotide acetate suspension for injection) demonstrated antitumor benefit in...

2009-01-13 06:45:00

Innovative Therapy Ensures Greater Patient Compliance, Improves Quality of Life MOUNTAIN VIEW, Calif., Jan. 13 /PRNewswire/ -- Based on its recent analysis of the biopharmaceuticals market, Frost & Sullivan recognizes Neotropix, Inc. with the 2009 U.S. Frost & Sullivan Award for Product Innovation of the Year. This award acknowledges the company's introduction of the innovative virotherapy NTX-010 (Seneca Valley Virus), an oncolytic picorna virus for treating small cell lung cancer...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.